Prevalence and Impact of COVID-19 on Maternal and Infant Health in African Populations

Completed

• Conditions: SARS-CoV2 Infection; COVID-19

• Registration Number: NCT05303168
• Lead Sponsor: Barcelona Institute for Global Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-3-10
• Last Update Posted: 23 September 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 1000

Inclusion Criteria

Inclusion Criteria:<br><br> - Permanent resident in the study area<br><br> - Agreement to deliver in the study site's maternity(ies) wards<br><br>Exclusion Criteria:<br><br> - Planning to move out the study area in the following 7 months from enrolment

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational [Patient Registry]
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of antibodies (Ig G and/or Ig M positive) against SARS-CoV-2 among pregnant women at delivery

Secondary Outcome Measures

Name	Time	Method
Incidence of SARS-CoV-2 infection during pregnancy;Maternal and neonatal morbidity due to SARS-CoV-2 infection during pregnancy;Maternal and neonatal mortality due to SARS-CoV-2 infection during pregnancy;Prevalence of pregnancy and perinatal adverse outcomes;Rate of vertical transmission of SARS-CoV-2 from infected mothers to their offspring, during the prenatal and perinatal period;CD4 cell counts;HIV viral load;Frequency of malaria parasitaemia at delivery (from maternal sample collected at delivery)